Benzinga  Sep 18  Comment 
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID) has exercised two additional options under its contract, which provides for GMP drug substance and drug product...
StreetInsider.com  Sep 9  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/WHO%3A+Number+of+New+Ebola+Cases+in+Liberia+%27Increasing+Exponentially%27+%28TKMR%29+%28BCRX%29+%28NNVC%29/9816532.html for the full story.
StreetInsider.com  Sep 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+Pharma+%28BCRX%29+Reports+RAPIVAB+Trial+Results+at+ICAAC+Meeting/9811983.html for the full story.
Benzinga  Sep 6  Comment 
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced trial results related to RAPIVABâ„¢ (peramivir injection), a neuraminidase inhibitor (NAI) for the treatment of influenza at the Interscience Conference on Antimicrobial Agents &...
Benzinga  Sep 5  Comment 
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares fell sharply after the World Health Organization posted a draft document suggesting it would not advise the company's Ebola therapy for use in humans until further safety data is...
StreetInsider.com  Sep 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+Pharma+%28BCRX%29+Reports+Event+of+Default+with+PhaRMA+Notes/9797034.html for the full story.
StreetInsider.com  Sep 2  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+Pharma+%28BCRX%29+to+Present+Peramivir+IV+Data+at+ICAAC/9796387.html for the full story.
Forbes  Aug 29  Comment 
The U.S. federal government is spreading its support for Ebola virus treatments across developers of biological and small molecule therapeutics. BioCryst has received an additional $2.4 million to accelerate their broad-spectrum antiviral, BCX-4430.
StreetInsider.com  Aug 29  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/BioCryst+Pharma+%28BCRX%29+Receives+%242.4M+Contract+Modification+from+NIAID+for+BCX4430+Efficacy+Study/9792949.html for the full story.
Forbes  Aug 26  Comment 
Looking back to 90 days ago, BioCryst Pharmaceuticals, Inc. (NASD: BCRX) priced a $100,000,000 secondary stock offering at $10.00 per share. Buyers in that offering made a considerable investment into the company, expecting that their investment...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki